NSE - Delayed Quote INR

Bajaj HealthCare Limited (BAJAJHCARE.NS)

551.00
-2.80
(-0.51%)
At close: 3:30:01 PM GMT+5:30
Loading Chart for BAJAJHCARE.NS
  • Previous Close 553.80
  • Open 558.45
  • Bid --
  • Ask --
  • Day's Range 546.70 - 566.95
  • 52 Week Range 263.30 - 745.00
  • Volume 186,342
  • Avg. Volume 361,279
  • Market Cap (intraday) 17.402B
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) --
  • EPS (TTM) -0.83
  • Earnings Date May 22, 2025 - May 26, 2025
  • Forward Dividend & Yield 1.00 (0.18%)
  • Ex-Dividend Date Sep 23, 2024
  • 1y Target Est --

Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 – amino – 1 – adamantanol, N – boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.

www.bajajhealth.com

1,049

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BAJAJHCARE.NS

View More

Performance Overview: BAJAJHCARE.NS

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

BAJAJHCARE.NS
3.91%
S&P BSE SENSEX (^BSESN)
4.08%

1-Year Return

BAJAJHCARE.NS
81.37%
S&P BSE SENSEX (^BSESN)
11.25%

3-Year Return

BAJAJHCARE.NS
83.29%
S&P BSE SENSEX (^BSESN)
54.05%

5-Year Return

BAJAJHCARE.NS
45.61%
S&P BSE SENSEX (^BSESN)
161.32%

Compare To: BAJAJHCARE.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAJAJHCARE.NS

View More

Valuation Measures

As of 5/13/2025
  • Market Cap

    17.47B

  • Enterprise Value

    18.95B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.05

  • Price/Book (mrq)

    3.92

  • Enterprise Value/Revenue

    3.63

  • Enterprise Value/EBITDA

    35.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.31%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    5.22B

  • Net Income Avi to Common (ttm)

    -6.65M

  • Diluted EPS (ttm)

    -0.83

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    228.4M

  • Total Debt/Equity (mrq)

    46.15%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BAJAJHCARE.NS

View More

People Also Watch